Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The Branford, CT-based company was founded in 2017 and plans to list on the Nasdaq under the symbol BTAI.
The acquisition will strengthen Charles River’s position as a global early-stage CRO, expanding its client base and service portfolio.
It’s the end of the road for Cambridge, MA based Enumeral Biomedical.
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers.
Companies including Sanofi, J&J, Nestle have dropped out.